Novartis has announced it is acquiring Gyroscope Therapeutics, the UK-based company behind an investigational dry ADM gene therapy that is the focus of key clinical trials in Australia.
Read More
Prof Robyn Guymer ‘thrilled’ by Phase 3 results of pegcetacoplan for dry AMD
Prominent Melbourne retinal disease researcher Professor Robyn Guymer is encouraged by the Phase 3 results of a trial she’s been involved in, investigating a new therapy she says is the only intervention shown to significantly slow the growth of lesions in dry AMD.
Read More
Read More